Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | ELANE | P08246 | 4/20 | 0.37 |
| ▸ | HTR6 | P50406 | 2/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | DTYMK | P23919 | 1/20 | 0.34 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3698821 | 0.89 | L3MBTL1 (0.36) | L3MBTL1BRD4EPHX1HTR6BCHE | |
| SCHEMBL3698710 | 0.86 | ELANE (0.41) | L3MBTL1BRD4ELANEHTR6BCHE | |
| SCHEMBL3704782 | 0.83 | ELANE (0.42) | L3MBTL1ELANEHTR6BCHE | |
| SCHEMBL3710717 | 0.82 | PTGER3 (0.41) | L3MBTL1HTR6BCHE | |
| SCHEMBL3702005 | 0.80 | PTGER3 (0.44) | L3MBTL1ELANE | |
| SCHEMBL3702550 | 0.79 | PTGER3 (0.47) | — | |
| SCHEMBL3708155 | 0.79 | P2RY1 (0.44) | — | |
| SCHEMBL3712537 | 0.79 | MEN1 (0.46) | L3MBTL1 | |
| SCHEMBL10150150 | 0.79 | SLC2A1 (0.37) | TBXAS1 | |
| SCHEMBL4569771 | 0.78 | L3MBTL1 (0.50) | L3MBTL1BRD4EPHX1ELANEHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8648086-B2 | 5,6-bicyclic heteroaryl-containing urea compounds as kinase inhibitors | ASCEPION PHARMACEUTICALS, INC. (CN) | 2014-02-11 | — | — | US | disclosed |
| US-8648086-B2 | 5,6-bicyclic heteroaryl-containing urea compounds as kinase inhibitors | ASCEPION PHARMACEUTICALS, INC. (CN) | 2014-02-11 | — | — | US | disclosed |
| US-8648086-B2 | 5,6-bicyclic heteroaryl-containing urea compounds as kinase inhibitors | ASCEPION PHARMACEUTICALS, INC. (CN) | 2014-02-11 | — | — | US | disclosed |
| US-20120122895-A1 | 5,6-BICYCLIC HETEROARYL-CONTAINING UREA COMPOUNDS AS KINASE INHIBITORS | JIANG, SHAN | 2012-05-17 | — | — | US | disclosed |
| US-20120122895-A1 | 5,6-BICYCLIC HETEROARYL-CONTAINING UREA COMPOUNDS AS KINASE INHIBITORS | JIANG, SHAN | 2012-05-17 | — | — | US | disclosed |
| US-20120122895-A1 | 5,6-BICYCLIC HETEROARYL-CONTAINING UREA COMPOUNDS AS KINASE INHIBITORS | JIANG, SHAN | 2012-05-17 | — | — | US | disclosed |
| WO-2011023081-A1 | 5,6-BICYCLIC HETEROARYL-CONTAINING UREA COMPOUNDS AS KINASE INHIBITORS | ASCEPION PHARMACEUTICALS, INC. (CN) | 2011-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122895-A1 | 5,6-BICYCLIC HETEROARYL-CONTAINING UREA COMPOUNDS AS KINASE INHIBITORS | FLT3, CSF1R, EPHA2 | L3MBTL1 4116/4885BRD4 2118/4885EPHX1 240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.